In this context, it is noteworthy that a TMPRSS2 inhibitor unable to interfere with SARS‐CoV‐2 infection upon systemic application in a rodent model was able to inhibit SARS‐CoV‐2 with high efficiency upon topical application.[40] Further, several TMPRSS2 inhibitors were found to efficiently block infection upon topical application in rodent models.[40, 41, 42, 43] Finally, aerosolized aprotinin, another protease inhibitor active against TMPRSS2, was shown to be well tolerated and of clinical benefit in COVID‐19 patients.[44]. The gene discussed is TMPRSS2; the disease is infection.